Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chordia Therapeutics

Request full access

Developing small molecule anti-cancer drugs targeting RNA deregulation

Fujisawa, JapanFounded 2017Biotech & Life Sciences

About Chordia Therapeutics

Chordia Therapeutics is a clinical-stage biotechnology company specializing in the research and development of small-molecule anti-cancer drugs. The company was established in October 2017 as a spin-out from Takeda Pharmaceutical by six of its drug discovery researchers. The founders include Hiroshi Miyake, who now serves as President and CEO, and Daisuke Morishita, the Chief Scientific Officer. Miyake has over two decades of experience in drug discovery and previously led the oncology drug discovery unit at Takeda. Inspired to enter molecular biology by a Nobel Prize winner, he pursued his Ph.D. in Pharmacology at the University of Tokyo before a 19-year career at Takeda. Morishita spent a decade at Takeda focusing on oncology therapeutics and cancer-related RNA networks.

The company focuses on a novel therapeutic strategy targeting RNA deregulation, which has been identified as a new characteristic of cancer. Its business model involves drug discovery through to clinical research, aiming for early monetization through strategic partnerships for manufacturing and sales in Japan, and out-licensing for overseas markets. Chordia Therapeutics went public, listing on the Tokyo Stock Exchange Growth Market in June 2024.

Chordia's pipeline was initiated with four programs licensed from Takeda. The lead asset is CTX-712, a first-in-class CLK inhibitor that works by causing splicing alterations to kill cancer cells. CTX-712 is in Phase 1/2 clinical trials in the US for hematologic malignancies, such as acute myeloid leukemia (AML). Another key asset, CTX-177 (a MALT1 inhibitor), was licensed to Ono Pharmaceutical in 2020 in a deal that included an upfront payment and potential milestones and royalties. The pipeline also includes preclinical assets like CTX-439, a CDK12 inhibitor, and GCN2 inhibitors.

Source: Dealroom company data

Chordia Therapeutics in the Fujisawa ecosystem

Live from Dealroom

The Chordia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Mitsubishi UFJ Capital
  • SMBC Venture Capital
  • Kyoto University Innovation Capital
  • Takeda Ventures
  • JAFCO

Series B and later1 investor entered at this stage

  • Takeda
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇯🇵 Japan100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chordia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chordia Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.